Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134734) titled 'AI-Driven Deciphering of Molecular Mechanisms Underlying KRAS Drug Resistance and Discovery & Optimization of Pan-KRAS Inhibitors' on Oct. 20.
Study Type: Observational study
Study Design:
Cross-sectional
Primary Sponsor: Shanghai General Hospital
Condition:
lung adenocarcinoma
Intervention:
KRAS-targeted drug sensitive patient group:None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-11-01
Target Sample Size: KRAS-targeted drug sensitive patient group:150;KRAS-targeted drug resistant patient group:150;
Countries of Recruitment:
China
To know more, visit https://www.c...